Essential factors influencing health-related-quality of life in psoriasis

Journal of Drugs in Dermatology

Volumn 13, Issue 3, 2014, Pages 246-250

  Mehren, Christine Rnøneberg ^a   Clemmensen, Anders ^a   Dall, Anne Boe Hansen ^a   Philipsen, Peter ^a   Gniadecki, Robert ^a,b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DERMATOLOGICAL LIFE QUALITY INDEX; HEALTH ASSESSMENT QUESTIONAIRE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE REGRESSION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SHORT FORM 36; YOUNG ADULT; ADOLESCENT; CROSS-SECTIONAL STUDY; FEMALE; MALE; PATHOPHYSIOLOGY; QUESTIONNAIRE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; AGED; ARTHRITIS, PSORIATIC; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84896322996     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Rapp SR, Feldman SR, Exum ML et al.Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41:401-407. (Pubitemid 29418506)
2. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008; 19:5-21 (Pubitemid 351252710)
3. Husted JA, Gladman DD, Farewell VT, Cook JR. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001; 45:151-158. (Pubitemid 32954441)
4. Zachariae H. Prevalence of joint disease in patients with psoriasis. Am J Clin Dermatol. 2003; 4: 441-447. (Pubitemid 36871763)
5. Garg A, Gladman D. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol. 2010; 63: 733-748.
6. de Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg.2009; 28:39-43
7. de Jong EM, Seegers BA, Gulinck MK et al.Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1728 patients. Dermatol. 1996; 193:300-303.
8. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med. 2009; 122:1150.e 1-9.
9. Kircik LH, Gonzalez ME. How and when to use biologics in psoriasis. J Drugs Dermatol. 2010; 9:106-117.
10. Kimball AB, Guerin A, Latremouille-Viau D et al.Coronary heart disease and stroke risk in patients with psoriasis: Retrospective analysis. Am J Med. 2010; 123:350-357.
11. Kimball AB, Gladman D, Gelfand JM et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58:1031-1042.
12. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54:2665-2673. (Pubitemid 44205029)
13. Harrison MJ, Davies LM, Bansback NJ et al.Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An investigation of the EQ-5D classification system.Value Health. 2009; 12:1026-1034.
14. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33:337-343. (Pubitemid 32675374)
15. Shikiar R,Willian MK, Okun MM et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes.2006; 4:71.
16. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003; 30:167-178. (Pubitemid 36077790)
17. Rosen CF, Mussani F, Chandran V et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012; 51:571-576.
18. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000; 80:430-434. (Pubitemid 32156226)
19. Zachariae H, Zachariae R, Blomqvist K et al.Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82:108-113. (Pubitemid 34596683)
20. Zanolli MD, Wikle JS. Joint complaints in psoriasis patients. Int J Dermatol.1992; 31:488-491.
21. Stern RS. The epidemiology of joint complaints in patients with psoriasis. J Rhematol. 1985; 12:315-320. (Pubitemid 15025376)
22. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003; 4:441-447. (Pubitemid 36871763)
23. Brockbank JE, Schentag C, Rosen C et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees. Arthritis Rheum. 2001; 44:S94.
24. Radtke MA, Reich K, Blome C et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol. 2009; 23:683-691.
25. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160:1040-1047.
26. Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology,clinical features, course, and outcome. Ann Rheum Dis. 2005; 64:suppl 2:ii14-17.
27. Mumtaz A, Gallagher P, Kirby B et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011; 70:272-277.
28. Shikiar R, Willian MK, Okun MM et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006; 4:71.
29. Spandonaro F, Altomare G, Berardesca E et al. Health-related quality of life in psoriasis: an analysis of Psocare project patients. G Ital Dermatol Venereol. 2011; 146:169-177.
30. Dubertret L, Mrowietz U, Ranki A et al. European patient perspective on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006; 155:729-736. (Pubitemid 44352553)
31. Schöffski O, Augustin M, Prinz J et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007; 5:209-218. (Pubitemid 46361354)
32. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, doubleblind, placebo-controlled, crossover trial. Lancet. 2009; 373:633-640.
33. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012; 166:179-188.
34. Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010; 59:40-49.
35. Kavanaugh A, Krueger GG, Beutler A et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007; 66:498-505. (Pubitemid 46580471)
36. Gelfand JM, Kimball AB, Mostow EN et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008; 11:400-407. (Pubitemid 351712967)
37. Gottlieb AB, Kircik L, Eisen D et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006; 17:343-352. (Pubitemid 46895587)
38. Gladman DD; ACCLAIM Study Investigators, Sampalis JS, Illouz O et al.Responses to adalimumab in patients with active psoriatic arthritis who have not adequatelyresponded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010; 37:1898-1906.
39. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007; 34:1040-1050. (Pubitemid 46774851)